CalciMedica Inc. (NASDAQ:CALC) Given Average Rating of “Hold” by Brokerages

Shares of CalciMedica Inc. (NASDAQ:CALC) have been assigned an average rating of “Hold” from the five research firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $10.00.

Several equities analysts have weighed in on the company. Guggenheim initiated coverage on CalciMedica in a report on Thursday. They set a “buy” rating for the company. HC Wainwright reaffirmed a “neutral” rating on shares of CalciMedica in a research note on Wednesday, July 29th. Weiss Ratings cut shares of CalciMedica from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 13th. Finally, UBS Group reaffirmed a “neutral” rating on shares of CalciMedica in a research report on Thursday, August 13th.

Insiders Place Their Bets

In other news, Director Fred A. Middleton bought 248,972 shares of the stock in a transaction on Thursday, June 25th. The stock was acquired at an average cost of $0.80 per share, for a total transaction of $199,177.60. Following the acquisition, the director owned 1,063,272 shares of the company’s stock, valued at $850,617.60. This represents a 30.57% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 28.25% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CalciMedica

Hedge funds have recently modified their holdings of the business. Jane Street Group LLC purchased a new stake in CalciMedica during the fourth quarter worth $127,000. Cetera Investment Advisers increased its holdings in shares of CalciMedica by 33.1% during the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock valued at $58,000 after acquiring an additional 9,045 shares in the last quarter. PVG Asset Management Corp purchased a new position in shares of CalciMedica in the fourth quarter worth $302,000. Boothbay Fund Management LLC purchased a new position in CalciMedica in the 4th quarter worth $506,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of CalciMedica by 26.1% during the fourth quarter. Renaissance Technologies LLC now owns 88,300 shares of the company’s stock worth $582,000 after purchasing an additional 18,300 shares during the period.

CalciMedica Price Performance

Shares of CalciMedica stock opened at $0.61 on Thursday. CalciMedica has a 52 week low of $0.46 and a 52 week high of $7.20. The company has a quick ratio of 5.58, a current ratio of 5.58 and a debt-to-equity ratio of 1.67. The company has a market capitalization of $9.69 million, a price-to-earnings ratio of -0.45 and a beta of 0.91. The stock’s 50-day simple moving average is $0.79 and its 200-day simple moving average is $0.71.

CalciMedica (NASDAQ:CALC) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.17). As a group, analysts expect that CalciMedica will post -1.05 earnings per share for the current fiscal year.

CalciMedica Company Profile

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.